Literature DB >> 9075933

T cell-mediated elimination of B7.2 transgenic B cells.

S Fournier1, J C Rathmell, C C Goodnow, J P Allison.   

Abstract

Transgenic mice were generated to explore the effects on lymphoid development and immune function of constitutive expression of murine B7.2 on B and T cells. The number of B lymphocytes in primary and secondary lymphoid tissues is normal in B7.2 transgenic lines expressing low levels of B7.2 on B cells, but markedly reduced in transgenic lines expressing moderate to high levels of the transgene on B cells. This reduction is not due to an intrinsic abnormality of the transgenic B cells, but is rather the consequence of an elimination by an immune mechanism requiring the engagement of CD28 on T cells. Interestingly, during cognate antigen-specific interaction with T cells in vivo, B7.2 transgenic B cells are not eliminated, but proliferate and differentiate normally. Our findings suggest that, in the absence of high affinity ligand for the TCR, the CD28-B7.2 system participates in the regulation of B cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075933     DOI: 10.1016/s1074-7613(00)80335-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  16 in total

1.  Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint.

Authors:  Joy A Williams; Karen S Hathcock; David Klug; Yohsuke Harada; Baishakhi Choudhury; James P Allison; Ryo Abe; Richard J Hodes
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

2.  Unregulated antigen-presenting cell activation by T cells breaks self tolerance.

Authors:  Jaeu Yi; Jisun Jung; Sung-Wook Hong; Jun Young Lee; Daehee Han; Kwang Soon Kim; Jonathan Sprent; Charles D Surh
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-31       Impact factor: 11.205

Review 3.  T cell costimulation, checkpoint inhibitors and anti-tumor therapy.

Authors:  Dipankar Nandi; Sanmoy Pathak; Taru Verma; Madhulika Singh; Avik Chattopadhyay; Samriddhi Thakur; Abinaya Raghavan; Abhijeet Gokhroo
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

Review 4.  Spontaneous ocular and neurologic deficits in transgenic mouse models of multiple sclerosis and noninvasive investigative modalities: a review.

Authors:  Archana A Gupta; Di Ding; Richard K Lee; Robert B Levy; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

Review 5.  The development of CD4+ T effector cells during the type 2 immune response.

Authors:  W C Gause; M Ekkens; D Nguyen; V Mitro; Q Liu; F D Finkelman; R J Greenwald; J F Urban
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 6.  Transgenic mouse models of multiple sclerosis.

Authors:  Tanja Scheikl; Béatrice Pignolet; Lennart T Mars; Roland S Liblau
Journal:  Cell Mol Life Sci       Date:  2010-08-17       Impact factor: 9.261

Review 7.  Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models.

Authors:  Lennart T Mars; Philippe Saikali; Roland S Liblau; Nathalie Arbour
Journal:  Biochim Biophys Acta       Date:  2010-07-15

8.  Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

Authors:  Christopher R Lucas; Hector M Cordero-Nieves; Robert S Erbe; Jaclyn W McAlees; Sumeena Bhatia; Richard J Hodes; Kerry S Campbell; Virginia M Sanders
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

9.  Regulation of thymic NKT cell development by the B7-CD28 costimulatory pathway.

Authors:  Joy A Williams; Joanne M Lumsden; Xiang Yu; Lionel Feigenbaum; Jingjing Zhang; Seth M Steinberg; Richard J Hodes
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  Hypercostimulation through 4-1BB distorts homeostasis of immune cells.

Authors:  Seung-Woo Lee; Shahram Salek-Ardakani; Robert S Mittler; Michael Croft
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.